India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia  | Date: 2022-01-18

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine
  • Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials.
  • If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine.

Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is reportedly working on an Omicron-specific vaccine that is likely to be ready in a couple of months. The potential vaccine might undergo a small trial in India before being exported as a booster shot or a standalone vaccine.

The apparent mRNA vaccine, produced specially to counter the recent Omicron variant, will be tested on humans first to know its efficiency and immunogenic soon.

The company had issued a press statement regarding the vaccine back in September 2021. It stated that the DCGI (Drug Controller General of India) had already approved the Phase II and Phase III study for the mRNA-based COVID-19 vaccine.

Gennova has already filed its Phase I study with the Central Drugs Standard Control Organization (CDSCO). Even the SEC (Subject Expert Committee) has deemed the company’s HGCO19 vaccine candidate as tolerable, safe, and immunogenic among the participants.

Meanwhile, Gennova has claimed that the Phase II and III study is being conducted across 15 and 27 sites in India, essentially using the DBT-ICMR trail network for its clinical study. If approved the vaccine for an emergency use authorization (EUA), it would be India’s first mRNA COVID-19 vaccine.

In other news, a recent Israeli trial found that Pfizer’s fourth dose is still insufficient to counter the Omicron variant. Although the fourth dose managed to increase the COVID-19 antibodies count in the participants, it was still “not good enough” to completely ward off the Omicron variant.

Some experts believe that Pfizer’s fourth dose could be used for those who are at the highest risk, but also suggested that it would be ideal to give the shot to senior citizens instead of to those just over the age of 60.

Source credits –

https://www.freepressjournal.in/india/punes-gennova-biopharmaceuticals-developing-covid-19-vaccine-for-omicron-variant

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...